KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short-term Investments (2020 - 2025)

Royalty Pharma (RPRX) has disclosed Short-term Investments for 6 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 67.7% to $18.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.8 million through Dec 2025, down 67.7% year-over-year, with the annual reading at $18.8 million for FY2025, 67.7% down from the prior year.
  • Short-term Investments hit $18.8 million in Q4 2025 for Royalty Pharma, up from $16.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $409.3 million in Q3 2022 to a low of $1.3 million in Q4 2022.
  • Historically, Short-term Investments has averaged $68.8 million across 5 years, with a median of $33.8 million in 2024.
  • Biggest YoY gain for Short-term Investments was 1307.69% in 2023; the steepest drop was 98.71% in 2023.
  • Year by year, Short-term Investments stood at $66.0 million in 2021, then plummeted by 98.03% to $1.3 million in 2022, then soared by 1307.69% to $18.3 million in 2023, then surged by 218.03% to $58.2 million in 2024, then tumbled by 67.7% to $18.8 million in 2025.
  • Business Quant data shows Short-term Investments for RPRX at $18.8 million in Q4 2025, $16.1 million in Q3 2025, and $13.2 million in Q2 2025.